Prothena (PRTA) Q1 Loss Narrower Than Expected, Updates View
Zacks Investment Research | May 10, 2017 01:52AM ET
Prothena Corporation plc (NASDAQ:PRTA) reported a loss of 99 cents per share in the first quarter of 2017, wider than the year-ago loss of 81 cents but narrower than the Zacks Consensus Estimate of $1.32.
Moreover, quarterly revenues were $0.3 million, roughly flat from the year-ago quarter and in line with the Zacks Consensus Estimate.
Prothena’s share price has increased 9.9% in the year so far, while the Zacks classified Medical-Biomedical and Genetics industry decreased 4.4%.
Quarter in Detail
Research and development (R&D) expenses were $25.7 million, up 25.4% year over year primarily due to increased personnel cost, and higher expenses for product manufacturing and clinical trials.
General and administrative (G&A) expenses were $10.8 million, up 50.8% year over year due to higher personnel costs, consulting expenses and other expenses.
During the quarter, the company raised aggregate net proceeds of $150.3 million through the issuance of 2.7 million ordinary shares in Mar 2017.
2017 Outlook
Prothena expects net cash from operating and investing activities in the range of $160–$170 million. The projected range included an expected milestone payment from Roche Holdings AG (OTC:RHHBY) upon initiation of the phase II study on PRX002. The company expects to end 2017 with approximately $375 million in cash, cash equivalents and restricted cash (midpoint). The guidance was updated to include the recent $150.3 million from the Mar 2017 public equity offering.
Pipeline Updates
Prothena continues to progress with its pipeline candidates. The company is evaluating its lead candidate NEOD001 in the phase III VITAL Amyloidosis study in newly diagnosed treatment-naïve patients with AL amyloidosis and cardiac dysfunction. Patient enrollment in the VITAL study is expected to be completed by mid-May 2017.
Prothena is also evaluating the candidate in a phase IIb study, PRONTO, in previously treated patients with AL amyloidosis and persistent cardiac dysfunction. The company completed enrollment in this study and top-line results from the study are expected following the 12-month study period in the second quarter of 2018.
Moreover, Prothena is evaluating PRX002, in collaboration with Roche, for the treatment of Parkinson’s disease and other related synucleinopathies. The company expects to initiate a phase II study, PASADENA, in patients suffering from Parkinson`s disease in the second quarter of 2017.
Get The News You Want
The company expects to report top-line data from a phase Ib multiple ascending dose, proof-of-biology study on PRX003 in patients with psoriasis in the third quarter of 2017.
Alongside, Prothena is also working to advance PRX004 in a phase I study in patients with ATTR amyloidosis. The candidate is expected to enter clinic in 2018.
Our Take
The narrower-than-expected loss in the first quarter was encouraging. Nevertheless, the company’s efforts on developing its pipeline are encouraging. We expect investor focus to remain on further updates from its late-stage candidate, NEOD001.
Zacks Rank & Key Picks
Prothena currently carries a Zacks Rank #4 (Sell).
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.